FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / Press Releases / Read Press Release


Sarepta Therapeutics Secures $40MM From Midcap Financial

June 29, 2015, 07:36 AM
Filed Under: Pharmaceuticals

Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, entered into a credit and security agreement with MidCap Financial, a middle market-focused, specialty finance firm, that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40 million at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20 million under the facility and has the right to repay all borrowed funds and terminate the facility at any time.

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other life threatening diseases.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.